JP2014528423A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014528423A5 JP2014528423A5 JP2014533486A JP2014533486A JP2014528423A5 JP 2014528423 A5 JP2014528423 A5 JP 2014528423A5 JP 2014533486 A JP2014533486 A JP 2014533486A JP 2014533486 A JP2014533486 A JP 2014533486A JP 2014528423 A5 JP2014528423 A5 JP 2014528423A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- patient
- combination
- rukoto
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002401 inhibitory effect Effects 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 24
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 22
- 239000003112 inhibitor Substances 0.000 claims description 22
- 201000002528 pancreatic cancer Diseases 0.000 claims description 22
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 17
- 229960005277 gemcitabine Drugs 0.000 claims description 17
- 238000001959 radiotherapy Methods 0.000 claims description 13
- 229960004316 cisplatin Drugs 0.000 claims description 11
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims description 11
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 10
- 229960005420 Etoposide Drugs 0.000 claims description 10
- 230000001235 sensitizing Effects 0.000 claims description 10
- 231100000202 sensitizing Toxicity 0.000 claims description 10
- 229960004562 Carboplatin Drugs 0.000 claims description 9
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims description 9
- 206010021143 Hypoxia Diseases 0.000 claims description 6
- 230000001146 hypoxic Effects 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims description 4
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 101710015564 CHEK1 Proteins 0.000 claims description 2
- 231100000277 DNA damage Toxicity 0.000 claims description 2
- 206010022114 Injury Diseases 0.000 claims description 2
- 101710013972 PLSCR1 Proteins 0.000 claims description 2
- 230000012820 cell cycle checkpoint Effects 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000002744 homologous recombination Methods 0.000 claims description 2
- 230000002452 interceptive Effects 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- 230000000865 phosphorylative Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 66
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- JZCWLJDSIRUGIN-UHFFFAOYSA-N CC(C)S(c(cc1)ccc1-c(nc1-c2cc(-c3ccc(CNC)cc3)n[o]2)cnc1N)(=O)=O Chemical compound CC(C)S(c(cc1)ccc1-c(nc1-c2cc(-c3ccc(CNC)cc3)n[o]2)cnc1N)(=O)=O JZCWLJDSIRUGIN-UHFFFAOYSA-N 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
Description
非小細胞肺癌について、本発明は、シスプラチン又はカルボプラチン、エトポシド、及び電離放射線と組み合わせたATR阻害剤での、非小細胞肺癌の治療方法に関する。出願者らは、35のヒト肺癌細胞株パネルに対する生存性アッセイにおいて、シスプラチン、エトポシド、ゲムシタビン、オキサリプラチン(oxaplatin)及びイリノテカンと組み合わせたATR阻害剤の共力効果を示し、並びに、シスプラチンと組み合わせた場合の、肺癌マウスモデルにおけるインビボ有効性を示している。
本発明は、例えば、以下を提供する:
(項目1)
次式:
から選択されるATR阻害剤を、ゲムシタビン、放射線治療、又はゲムシタビンと放射線治療の両方を合わせたものから選択される別の癌治療と組み合わせて、患者に投与することにより、該患者体内の膵臓癌を治療する方法。
(項目2)
次式:
から選択されるATR阻害剤を、ゲムシタビン又は放射線治療から選択される癌治療と組み合わせて、患者に投与することにより、該患者体内の膵臓癌細胞の該癌治療に対する感受性を増感させる方法。
(項目3)
前記癌治療がゲムシタビンである、項目1に記載の方法。
(項目4)
前記癌治療が放射線治療である、項目1に記載の方法。
(項目5)
次式:
から選択されるATR阻害剤を、ゲムシタビン又は放射線治療から選択される癌治療と組み合わせて、患者に投与することにより、低酸素状態膵臓癌細胞を該癌治療に対して感作させる方法。
(項目6)
次式:
から選択されるATR阻害剤を、ゲムシタビン及び/又は放射線と組み合わせて患者に投与することを含む、膵臓癌細胞におけるChk1(Ser 345)のリン酸化を阻害する方法。
(項目7)
次式:
から選択されるATR阻害剤を、放射線治療と組み合わせて患者に投与することによる、低酸素状態膵臓癌細胞を放射線感作させる方法。
(項目8)
次式:
から選択されるATR阻害剤を、ゲムシタビンと組み合わせて患者に投与することによる、低酸素状態膵臓癌細胞を感作させる方法。
(項目9)
次式:
から選択されるATR阻害剤を、化学放射線と組み合わせて患者に投与することにより、膵臓癌細胞を化学放射線に対して感作させる方法。
(項目10)
前記化学療法がゲムシタビンである、項目9に記載の方法。
(項目11)
次式:
から選択されるATR阻害剤を、放射線治療と組み合わせて患者に投与することにより、損傷誘発された細胞周期チェックポイントを妨害する方法。
(項目12)
次式:
から選択されるATR阻害剤を、放射線治療と組み合わせて患者に投与することにより、膵臓癌細胞の相同組換えによるDNA損傷修復を阻害する方法。
(項目13)
前記膵臓癌細胞が、PSN−1、MiaPaCa−2又はPanc−1から選択される膵臓細胞株から誘導される、項目1〜12のいずれか一項に記載の方法。
(項目14)
前記膵臓癌細胞が、癌患者の体内にある、項目1〜12のいずれか一項に記載の方法。
(項目15)
前記化合物が患者に投与される、項目1〜12のいずれか一項に記載の方法。
(項目16)
前記化合物が膵臓癌細胞に投与される、項目1〜12のいずれか一項に記載の方法。
(項目17)
患者の体内の非小細胞肺癌を治療する方法であって、式821又は822:
の化合物を、シスプラチン又はカルボプラチン、エトポシド、及び電離放射線のうちの1つ以上の追加治療薬と組み合わせて該患者に投与することを含む、方法。
(項目18)
式821又は822の化合物を、シスプラチン又はカルボプラチン、エトポシド、及び電離放射線からなる癌治療と組み合わせて患者に投与することを含む、項目17に記載の方法。
(項目19)
前記癌治療がシスプラチン又はカルボプラチン及びエトポシドである、項目18に記載の方法。
(項目20)
前記癌治療がシスプラチン又はカルボプラチン及びエトポシド並びに電離放射線である、項目18に記載の方法。
(項目21)
前記癌治療が電離放射線である、項目18に記載の方法。
(項目22)
前記ATR阻害剤が822である、項目1〜21のいずれか一項に記載の方法。
本発明は、例えば、以下を提供する:
(項目1)
次式:
から選択されるATR阻害剤を、ゲムシタビン、放射線治療、又はゲムシタビンと放射線治療の両方を合わせたものから選択される別の癌治療と組み合わせて、患者に投与することにより、該患者体内の膵臓癌を治療する方法。
(項目2)
次式:
から選択されるATR阻害剤を、ゲムシタビン又は放射線治療から選択される癌治療と組み合わせて、患者に投与することにより、該患者体内の膵臓癌細胞の該癌治療に対する感受性を増感させる方法。
(項目3)
前記癌治療がゲムシタビンである、項目1に記載の方法。
(項目4)
前記癌治療が放射線治療である、項目1に記載の方法。
(項目5)
次式:
から選択されるATR阻害剤を、ゲムシタビン又は放射線治療から選択される癌治療と組み合わせて、患者に投与することにより、低酸素状態膵臓癌細胞を該癌治療に対して感作させる方法。
(項目6)
次式:
から選択されるATR阻害剤を、ゲムシタビン及び/又は放射線と組み合わせて患者に投与することを含む、膵臓癌細胞におけるChk1(Ser 345)のリン酸化を阻害する方法。
(項目7)
次式:
から選択されるATR阻害剤を、放射線治療と組み合わせて患者に投与することによる、低酸素状態膵臓癌細胞を放射線感作させる方法。
(項目8)
次式:
から選択されるATR阻害剤を、ゲムシタビンと組み合わせて患者に投与することによる、低酸素状態膵臓癌細胞を感作させる方法。
(項目9)
次式:
から選択されるATR阻害剤を、化学放射線と組み合わせて患者に投与することにより、膵臓癌細胞を化学放射線に対して感作させる方法。
(項目10)
前記化学療法がゲムシタビンである、項目9に記載の方法。
(項目11)
次式:
から選択されるATR阻害剤を、放射線治療と組み合わせて患者に投与することにより、損傷誘発された細胞周期チェックポイントを妨害する方法。
(項目12)
次式:
から選択されるATR阻害剤を、放射線治療と組み合わせて患者に投与することにより、膵臓癌細胞の相同組換えによるDNA損傷修復を阻害する方法。
(項目13)
前記膵臓癌細胞が、PSN−1、MiaPaCa−2又はPanc−1から選択される膵臓細胞株から誘導される、項目1〜12のいずれか一項に記載の方法。
(項目14)
前記膵臓癌細胞が、癌患者の体内にある、項目1〜12のいずれか一項に記載の方法。
(項目15)
前記化合物が患者に投与される、項目1〜12のいずれか一項に記載の方法。
(項目16)
前記化合物が膵臓癌細胞に投与される、項目1〜12のいずれか一項に記載の方法。
(項目17)
患者の体内の非小細胞肺癌を治療する方法であって、式821又は822:
の化合物を、シスプラチン又はカルボプラチン、エトポシド、及び電離放射線のうちの1つ以上の追加治療薬と組み合わせて該患者に投与することを含む、方法。
(項目18)
式821又は822の化合物を、シスプラチン又はカルボプラチン、エトポシド、及び電離放射線からなる癌治療と組み合わせて患者に投与することを含む、項目17に記載の方法。
(項目19)
前記癌治療がシスプラチン又はカルボプラチン及びエトポシドである、項目18に記載の方法。
(項目20)
前記癌治療がシスプラチン又はカルボプラチン及びエトポシド並びに電離放射線である、項目18に記載の方法。
(項目21)
前記癌治療が電離放射線である、項目18に記載の方法。
(項目22)
前記ATR阻害剤が822である、項目1〜21のいずれか一項に記載の方法。
Claims (22)
- 前記癌治療がゲムシタビンである、請求項1に記載の組成物。
- 前記癌治療が放射線治療である、請求項1に記載の組成物。
- 前記化学療法がゲムシタビンである、請求項9に記載の組成物。
- 前記膵臓癌細胞が、PSN−1、MiaPaCa−2又はPanc−1から選択される膵臓細胞株から誘導される、請求項1〜12のいずれか一項に記載の組成物。
- 前記膵臓癌細胞が、癌患者の体内にある、請求項1〜12のいずれか一項に記載の組成物。
- 前記組成物が患者に投与される、請求項1〜12のいずれか一項に記載の組成物。
- 前記組成物が膵臓癌細胞に投与される、請求項1〜12のいずれか一項に記載の組成物。
- 前記組成物は、シスプラチン又はカルボプラチン、エトポシド、及び電離放射線からなる癌治療と組み合わせて患者に投与されることを特徴とする、請求項17に記載の組成物。
- 前記癌治療がシスプラチン又はカルボプラチン及びエトポシドである、請求項18に記載の組成物。
- 前記癌治療がシスプラチン又はカルボプラチン及びエトポシド並びに電離放射線である、請求項18に記載の組成物。
- 前記癌治療が電離放射線である、請求項18に記載の組成物。
- 前記ATR阻害剤が822である、請求項1〜21のいずれか一項に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161542084P | 2011-09-30 | 2011-09-30 | |
US61/542,084 | 2011-09-30 | ||
PCT/US2012/058374 WO2013049859A1 (en) | 2011-09-30 | 2012-10-01 | Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017076560A Division JP2017119724A (ja) | 2011-09-30 | 2017-04-07 | Atr阻害剤による膵臓癌及び非小細胞肺癌の治療 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014528423A JP2014528423A (ja) | 2014-10-27 |
JP2014528423A5 true JP2014528423A5 (ja) | 2015-11-19 |
JP6162126B2 JP6162126B2 (ja) | 2017-08-23 |
Family
ID=47019166
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014533486A Active JP6162126B2 (ja) | 2011-09-30 | 2012-10-01 | Atr阻害剤による膵臓癌及び非小細胞肺癌の治療 |
JP2017076560A Withdrawn JP2017119724A (ja) | 2011-09-30 | 2017-04-07 | Atr阻害剤による膵臓癌及び非小細胞肺癌の治療 |
JP2018092027A Pending JP2018119014A (ja) | 2011-09-30 | 2018-05-11 | Atr阻害剤による膵臓癌及び非小細胞肺癌の治療 |
JP2019229321A Active JP7162585B2 (ja) | 2011-09-30 | 2019-12-19 | Atr阻害剤による膵臓癌及び非小細胞肺癌の治療 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017076560A Withdrawn JP2017119724A (ja) | 2011-09-30 | 2017-04-07 | Atr阻害剤による膵臓癌及び非小細胞肺癌の治療 |
JP2018092027A Pending JP2018119014A (ja) | 2011-09-30 | 2018-05-11 | Atr阻害剤による膵臓癌及び非小細胞肺癌の治療 |
JP2019229321A Active JP7162585B2 (ja) | 2011-09-30 | 2019-12-19 | Atr阻害剤による膵臓癌及び非小細胞肺癌の治療 |
Country Status (16)
Country | Link |
---|---|
US (3) | US20130089626A1 (ja) |
EP (2) | EP3733185B1 (ja) |
JP (4) | JP6162126B2 (ja) |
KR (1) | KR102056586B1 (ja) |
CN (3) | CN103957917A (ja) |
AU (3) | AU2012315384B2 (ja) |
BR (1) | BR112014007690B1 (ja) |
CA (2) | CA3089792C (ja) |
ES (2) | ES2940121T3 (ja) |
IL (1) | IL231813B (ja) |
IN (1) | IN2014CN02501A (ja) |
MX (2) | MX2014003785A (ja) |
RU (2) | RU2018108589A (ja) |
SG (2) | SG10201602515QA (ja) |
WO (1) | WO2013049859A1 (ja) |
ZA (1) | ZA201402627B (ja) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG172248A1 (en) | 2008-12-19 | 2011-07-28 | Vertex Pharma | Pyrazine derivatives useful as inhibitors of atr kinase |
CA2798763A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2569284B1 (en) | 2010-05-12 | 2015-07-08 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as inhibitors of atr kinase |
WO2011143399A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US9062008B2 (en) | 2010-05-12 | 2015-06-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
EP2569287B1 (en) | 2010-05-12 | 2014-07-09 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
WO2011143419A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Pyrazines useful as inhibitors of atr kinase |
NZ605627A (en) | 2010-06-23 | 2015-06-26 | Vertex Pharma | Pyrrolo-pyrazine derivatives useful as inhibitors of atr kinase |
WO2012138938A1 (en) | 2011-04-05 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Aminopyrazine compounds useful as inhibitors of tra kinase |
EP2723747A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2012178123A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US8765751B2 (en) | 2011-09-30 | 2014-07-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8846686B2 (en) | 2011-09-30 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
EP3878851A1 (en) | 2011-09-30 | 2021-09-15 | Vertex Pharmaceuticals Incorporated | Process for making compounds useful as inhibitors of atr kinase |
CN103957917A (zh) | 2011-09-30 | 2014-07-30 | 沃泰克斯药物股份有限公司 | 用atr抑制剂治疗胰腺癌和非小细胞肺癌 |
EP2776420A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
US8846917B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2013071094A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
EP2776419B1 (en) | 2011-11-09 | 2016-05-11 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
PL2833973T3 (pl) * | 2012-04-05 | 2018-02-28 | Vertex Pharmaceuticals Incorporated | Związki użyteczne jako inhibitory kinazy ATR i ich terapie skojarzone |
EP2904406B1 (en) | 2012-10-04 | 2018-03-21 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
WO2014062604A1 (en) | 2012-10-16 | 2014-04-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
BR112015012454B1 (pt) | 2012-12-07 | 2022-07-05 | Vertex Pharmaceuticals Incorporated | Compostos inibidores de atr quinase, seu uso e composição farmacêutica compreendendo os mesmos |
US9663519B2 (en) | 2013-03-15 | 2017-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9644037B2 (en) | 2013-10-18 | 2017-05-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 and their use |
SG11201604519PA (en) | 2013-12-06 | 2016-07-28 | Vertex Pharma | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof |
EP3152212B9 (en) | 2014-06-05 | 2020-05-27 | Vertex Pharmaceuticals Inc. | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof |
WO2015195740A1 (en) * | 2014-06-17 | 2015-12-23 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of chk1 and atr inhibitors |
TWI656121B (zh) | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | 2-(嗎啉-4-基)-1,7-萘啶 |
US20190000850A1 (en) * | 2015-02-09 | 2019-01-03 | The Regents Of The University Of California | Combination cancer therapy |
US11464774B2 (en) * | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
US10570119B2 (en) | 2016-01-11 | 2020-02-25 | Merrimack Pharmaceuticals, Inc. | Inhibiting ataxia telangiectasia and Rad3-related protein (ATR) |
US11730734B2 (en) | 2016-09-12 | 2023-08-22 | University Of Florida Research Foundation, Incorporated | Use of ATR and Chk1 inhibitor compounds |
EA039513B1 (ru) * | 2017-01-09 | 2022-02-04 | Селатор Фармасьютикалз, Инк. | Ингибитор атаксии-телеангиэкстазии и rad3-родственного белка (atr) и содержащие его липосомные композиции |
WO2018153972A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors and antiandrogens |
JOP20190197A1 (ar) | 2017-02-24 | 2019-08-22 | Bayer Pharma AG | مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر |
AR110995A1 (es) | 2017-02-24 | 2019-05-22 | Bayer Ag | Combinación de inhibidores de quinasa atr con sal de radio-223 |
WO2018153971A1 (en) * | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors |
WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
EP3661560A1 (en) | 2017-08-04 | 2020-06-10 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors |
EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
WO2019110586A1 (en) | 2017-12-08 | 2019-06-13 | Bayer Aktiengesellschaft | Predictive markers for atr kinase inhibitors |
CN111526889B (zh) * | 2017-12-29 | 2023-06-02 | 沃泰克斯药物股份有限公司 | 使用atr抑制剂治疗癌症的方法 |
WO2020064971A1 (en) | 2018-09-26 | 2020-04-02 | Merck Patent Gmbh | Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer |
EP3866785A1 (en) | 2018-10-15 | 2021-08-25 | Merck Patent GmbH | Combination therapy utilizing dna alkylating agents and atr inhibitors |
CA3116230A1 (en) | 2018-10-16 | 2020-04-23 | Bayer Aktiengesellschaft | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |
US11801246B2 (en) | 2018-11-09 | 2023-10-31 | East Tennessee State University Research Foundatio | Methods of treating ischemic disease by administering an ATR kinase inhibitor |
US20220274929A1 (en) * | 2019-02-25 | 2022-09-01 | The Regents Of The University Of California | Thiosemicarbazone compounds and uses thereof |
EP4237421A1 (en) | 2020-11-02 | 2023-09-06 | Trethera Corporation | Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof |
CN113073139A (zh) * | 2021-04-06 | 2021-07-06 | 浙江大学 | 一种胰腺癌肿瘤标志物及其应用 |
CN115300512B (zh) * | 2022-08-05 | 2024-01-12 | 华中科技大学同济医学院附属协和医院 | Atr抑制剂ve-822在治疗肺腺癌中的应用 |
Family Cites Families (218)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4309430A (en) | 1980-06-27 | 1982-01-05 | Merck & Co., Inc. | Pyrazinyl-1,2,4-oxadiazole-5-ones, for treatment of edema, and processes for preparing same |
JPS62270623A (ja) | 1985-12-07 | 1987-11-25 | Daicel Chem Ind Ltd | ビス(4−アミノフエニル)ピラジンおよびその製法、ならびにポリイミドおよびその製法 |
JPS63208520A (ja) | 1987-02-26 | 1988-08-30 | Terumo Corp | ピラジン誘導体を含有する血小板凝集抑制剤 |
US5329012A (en) | 1987-10-29 | 1994-07-12 | The Research Foundation Of State University Of New York | Bis(acyloxmethyl)imidazole compounds |
JP2597917B2 (ja) | 1990-04-26 | 1997-04-09 | 富士写真フイルム株式会社 | 新規な色素形成カプラー及びそれを用いたハロゲン化銀カラー写真感光材料 |
US5572248A (en) | 1994-09-19 | 1996-11-05 | Teleport Corporation | Teleconferencing method and system for providing face-to-face, non-animated teleconference environment |
EP0914318A1 (en) | 1996-05-11 | 1999-05-12 | Kings College London | Pyrazines |
JP2002241379A (ja) | 1997-03-21 | 2002-08-28 | Dainippon Pharmaceut Co Ltd | 3−オキサジアゾリルキノキサリン誘導体 |
AU2790999A (en) | 1998-03-03 | 1999-09-20 | Merck & Co., Inc. | Fused piperidine substituted arylsulfonamides as beta3-agonists |
DE19826671A1 (de) | 1998-06-16 | 1999-12-23 | Hoechst Schering Agrevo Gmbh | 1,3-Oxazolin- und 1,3-Thiazolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel |
TW548275B (en) | 1998-07-16 | 2003-08-21 | Shionogi & Co | A pyrimidine derivative having antiturnor activity |
US7023913B1 (en) | 2000-06-14 | 2006-04-04 | Monroe David A | Digital security multimedia sensor |
DK1150999T3 (da) | 1999-02-05 | 2006-10-30 | Debiopharm Sa | Cyclosporinderivater og fremgangsmåde til fremstilling deraf |
US6738073B2 (en) | 1999-05-12 | 2004-05-18 | Imove, Inc. | Camera system with both a wide angle view and a high resolution view |
EP1377554A1 (en) | 1999-06-16 | 2004-01-07 | University Of Iowa Research Foundation | Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases |
US7015954B1 (en) | 1999-08-09 | 2006-03-21 | Fuji Xerox Co., Ltd. | Automatic video system using multiple cameras |
US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
AU782858B2 (en) | 1999-12-17 | 2005-09-01 | Novartis Vaccines And Diagnostics, Inc. | Pyrazine based inhibitors of glycogen synthase kinase 3 |
US6849660B1 (en) | 2000-08-01 | 2005-02-01 | Isis Pharmaceuticals, Inc. | Antimicrobial biaryl compounds |
JP2002072370A (ja) | 2000-08-29 | 2002-03-12 | Fuji Photo Optical Co Ltd | ペーパーマガジン及び写真焼付装置 |
JP2002072372A (ja) | 2000-09-04 | 2002-03-12 | Fuji Photo Film Co Ltd | 画像形成用シート体の切断装置 |
US6829391B2 (en) | 2000-09-08 | 2004-12-07 | Siemens Corporate Research, Inc. | Adaptive resolution system and method for providing efficient low bit rate transmission of image data for distributed applications |
EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
US8085293B2 (en) | 2001-03-14 | 2011-12-27 | Koninklijke Philips Electronics N.V. | Self adjusting stereo camera system |
US6759657B2 (en) | 2001-03-27 | 2004-07-06 | Kabushiki Kaisha Toshiba | Infrared sensor |
WO2002080899A1 (fr) | 2001-03-30 | 2002-10-17 | Eisai Co., Ltd. | Agent de traitement de maladie digestive |
US6469002B1 (en) | 2001-04-19 | 2002-10-22 | Millennium Pharmaceuticals, Inc. | Imidazolidine compounds |
DE60229059D1 (de) | 2001-05-08 | 2008-11-06 | Univ Yale | Proteomimetische verbindungen und verfahren |
SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
SE0102438D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
JP2003074370A (ja) | 2001-09-05 | 2003-03-12 | Suzuki Motor Corp | エンジンのベルト保護装置 |
USRE40794E1 (en) | 2001-09-26 | 2009-06-23 | Merck & Co., Inc. | Crystalline forms of carbapenem antibiotics and methods of preparation |
GB0124939D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
AU2002343557A1 (en) | 2001-11-21 | 2003-06-10 | Pharmacia And Upjohn Company | Substituted aryl 1,4-pyrazine derivatives |
US6992087B2 (en) | 2001-11-21 | 2006-01-31 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
EP2322521B1 (en) | 2002-02-06 | 2013-09-04 | Vertex Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of GSK-3 |
BR0307575A (pt) | 2002-03-13 | 2004-12-21 | Janssen Pharmaceutica Nv | Derivados de sulfonila como inibidores de histona desacetilase |
GB0206860D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
US7043079B2 (en) | 2002-04-25 | 2006-05-09 | Microsoft Corporation | “Don't care” pixel interpolation |
GB0209715D0 (en) | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
CA2484209C (en) | 2002-05-03 | 2013-06-11 | Exelixis, Inc. | Protein kinase modulators and methods of use |
KR20050004214A (ko) | 2002-05-31 | 2005-01-12 | 에자이 가부시키가이샤 | 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물 |
WO2004000820A2 (en) | 2002-06-21 | 2003-12-31 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
AU2003249369A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain amino-substituted monocycles as kinase modulators |
WO2004033431A2 (en) | 2002-10-04 | 2004-04-22 | Arena Pharmaceuticals, Inc. | Hydroxypyrazoles for use against metabolic-related disorders |
US20040075741A1 (en) | 2002-10-17 | 2004-04-22 | Berkey Thomas F. | Multiple camera image multiplexer |
US7385626B2 (en) | 2002-10-21 | 2008-06-10 | Sarnoff Corporation | Method and system for performing surveillance |
US20040100560A1 (en) | 2002-11-22 | 2004-05-27 | Stavely Donald J. | Tracking digital zoom in a digital video camera |
SE0203754D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
SE0203752D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
OA13151A (en) | 2003-02-26 | 2006-12-13 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors. |
US7684624B2 (en) | 2003-03-03 | 2010-03-23 | Smart Technologies Ulc | System and method for capturing images of a target area on which information is recorded |
ES2308151T3 (es) | 2003-03-11 | 2008-12-01 | Pfizer Products Inc. | Compuestos de pirazina como inhibidores del factor de crecimiento transformante (tgf). |
EP1606266A4 (en) | 2003-03-21 | 2008-06-25 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
AU2004224392A1 (en) | 2003-03-24 | 2004-10-07 | Merck & Co., Inc. | Biaryl substituted 6-membered heterocyles as sodium channel blockers |
GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
GB2400514B (en) | 2003-04-11 | 2006-07-26 | Hewlett Packard Development Co | Image capture method |
CA2524867A1 (en) | 2003-05-15 | 2004-12-02 | Merck & Co., Inc. | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
WO2004103991A1 (fr) | 2003-05-20 | 2004-12-02 | 'chemical Diversity Research Institute', Ltd. | Piperidines 2-substituees, bibliotheque focalisee et composition pharmaceutique |
US20050123902A1 (en) | 2003-05-21 | 2005-06-09 | President And Fellows Of Harvard College | Human papillomavirus inhibitors |
PE20050206A1 (es) * | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
US7986339B2 (en) | 2003-06-12 | 2011-07-26 | Redflex Traffic Systems Pty Ltd | Automated traffic violation monitoring and reporting system with combined video and still-image data |
JP2005020227A (ja) | 2003-06-25 | 2005-01-20 | Pfu Ltd | 画像圧縮装置 |
TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
WO2005034952A2 (en) | 2003-10-07 | 2005-04-21 | The Feinstein Institute For Medical Research | Isoxazole and isothiazole compounds useful in the treatment of inflammation |
US20050116968A1 (en) | 2003-12-02 | 2005-06-02 | John Barrus | Multi-capability display |
US20080194574A1 (en) | 2003-12-16 | 2008-08-14 | Axxima Pharmaceuticals Ag | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases |
CA2555402A1 (en) | 2004-02-12 | 2005-09-01 | Celine Bonnefous | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 |
US20050276765A1 (en) | 2004-06-10 | 2005-12-15 | Paul Nghiem | Preventing skin damage |
US20080153869A1 (en) | 2004-06-14 | 2008-06-26 | Bressi Jerome C | Kinase Inhibitors |
US7452993B2 (en) | 2004-07-27 | 2008-11-18 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
US7626021B2 (en) | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
WO2006021884A2 (en) | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
JP2008510792A (ja) | 2004-08-26 | 2008-04-10 | ファイザー・インク | タンパク質チロシンキナーゼ阻害剤としてのアミノヘテロアリール化合物 |
US7730406B2 (en) | 2004-10-20 | 2010-06-01 | Hewlett-Packard Development Company, L.P. | Image processing system and method |
JP5008569B2 (ja) | 2004-10-22 | 2012-08-22 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | C−fmsキナーゼのインヒビターとしての芳香族アミド |
WO2006053342A2 (en) | 2004-11-12 | 2006-05-18 | Osi Pharmaceuticals, Inc. | Integrin antagonists useful as anticancer agents |
EP1814882A1 (en) | 2004-11-22 | 2007-08-08 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
JP4810669B2 (ja) | 2004-11-25 | 2011-11-09 | コニカミノルタホールディングス株式会社 | 有機エレクトロルミネッセンス素子、表示装置及び照明装置 |
GB0428235D0 (en) | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Novel compounds |
JP2008525453A (ja) | 2004-12-27 | 2008-07-17 | アルコン,インコーポレイティド | 緑内障と、rhoキナーゼを媒介とした他の疾患および症状を治療するためのアミノピラジン・アナログ |
GB0500492D0 (en) | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
CA2598456A1 (en) | 2005-02-16 | 2006-08-24 | Schering Corporation | Heterocyclic substituted piperazines with cxcr3 antagonist activity |
WO2006114180A1 (de) | 2005-04-25 | 2006-11-02 | Merck Patent Gmbh | Neuartige aza-heterozyklen als kinase-inhibitoren |
WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
CA2610884A1 (en) | 2005-06-09 | 2006-12-21 | Merck & Co., Inc. | Inhibitors of checkpoint kinases |
MX2008001538A (es) | 2005-08-02 | 2008-04-04 | Lexicon Pharmaceuticals Inc | Aril piridinas y metodos para su uso. |
WO2007015632A1 (en) | 2005-08-04 | 2007-02-08 | Cgk Co., Ltd. | Atm and atr inhibitor |
US7394926B2 (en) | 2005-09-30 | 2008-07-01 | Mitutoyo Corporation | Magnified machine vision user interface |
US7806604B2 (en) | 2005-10-20 | 2010-10-05 | Honeywell International Inc. | Face detection and tracking in a wide field of view |
AR056786A1 (es) | 2005-11-10 | 2007-10-24 | Smithkline Beecham Corp | Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com |
CA2630460C (en) | 2005-12-01 | 2013-01-08 | F. Hoffmann-La Roche Ag | Heteroaryl substituted piperidine derivatives as l-cpt1 inhibitors |
EP1970377A4 (en) | 2005-12-09 | 2013-02-27 | Meiji Seika Kaisha | LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THIS AS AN ACTIVE SUBSTANCE |
JP2009519937A (ja) | 2005-12-14 | 2009-05-21 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 無脊椎有害生物防除用イソオキサゾリン |
CA2629342A1 (en) | 2005-12-22 | 2007-07-05 | Alcon Research, Ltd. | (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions |
PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
ITMI20060311A1 (it) | 2006-02-21 | 2007-08-22 | Btsr Int Spa | Dispositivo perfezionato di alimentazione di filo o filatio ad una macchina tessile e metodo per attuare tale alimentazione |
GB0603684D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
WO2007096764A2 (en) | 2006-02-27 | 2007-08-30 | Glenmark Pharmaceuticals S.A. | Bicyclic heteroaryl derivatives as cannabinoid receptor modulators |
TW200800203A (en) | 2006-03-08 | 2008-01-01 | Astrazeneca Ab | New use |
DE602007004092D1 (de) | 2006-03-22 | 2010-02-11 | Vertex Pharma | C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen |
US7574131B2 (en) | 2006-03-29 | 2009-08-11 | Sunvision Scientific Inc. | Object detection system and method |
MX2008012658A (es) | 2006-03-31 | 2008-12-16 | Schering Corp | Inhibidores de cinasa. |
US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
CN101472912A (zh) | 2006-06-22 | 2009-07-01 | 比奥维特罗姆上市公司 | 作为mnk激酶抑制剂的吡啶和吡嗪衍生物 |
JP2009541323A (ja) | 2006-06-22 | 2009-11-26 | マリンクロット インコーポレイテッド | 拡張された共役を有するピラジン誘導体およびその使用 |
EP1900727A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Aminopyridine derivatives as kinase inhibitors |
WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
GB0619342D0 (en) | 2006-09-30 | 2006-11-08 | Vernalis R&D Ltd | New chemical compounds |
CA2664119A1 (en) | 2006-10-04 | 2008-04-10 | F. Hoffmann-La Roche Ag | 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents |
EP2078016B1 (en) | 2006-10-19 | 2012-02-01 | Signal Pharmaceuticals LLC | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
WO2008060907A2 (en) | 2006-11-10 | 2008-05-22 | Bristol-Myers Squibb Company | Pyrrolo-pyridine kinase inhibitors |
US20080132698A1 (en) | 2006-11-30 | 2008-06-05 | University Of Ottawa | Use of N-oxide compounds in coupling reactions |
UY30796A1 (es) | 2006-12-15 | 2008-07-31 | Bayer Schering Pharma Ag | 3-h-pirazolopiridinas y sales de éstas, composiciones farmacéuticas que las comprenden, métodos para prepararlas, y sus usos |
WO2008079291A2 (en) | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
PE20081581A1 (es) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
GB0625659D0 (en) | 2006-12-21 | 2007-01-31 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
US8314087B2 (en) | 2007-02-16 | 2012-11-20 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and methods of use |
CA2679659C (en) | 2007-03-01 | 2016-01-19 | Novartis Ag | Pim kinase inhibitors and methods of their use |
JP2008260691A (ja) | 2007-04-10 | 2008-10-30 | Bayer Cropscience Ag | 殺虫性アリールイソオキサゾリン誘導体 |
WO2008122375A2 (en) | 2007-04-10 | 2008-10-16 | Bayer Cropscience Ag | Insecticidal aryl isoxazoline derivatives |
PE20090288A1 (es) | 2007-05-10 | 2009-04-03 | Smithkline Beecham Corp | Derivados de quinoxalina como inhibidores de la pi3 quinasa |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
UY31137A1 (es) | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | Derivados de quinazolina como inhibidores de la pi3 quinasa |
JP2009027904A (ja) | 2007-06-19 | 2009-02-05 | Hitachi Ltd | 回転電機 |
EP2012409A2 (en) | 2007-06-19 | 2009-01-07 | Hitachi, Ltd. | Rotating electrical machine |
JPWO2008156174A1 (ja) | 2007-06-21 | 2010-08-26 | 大正製薬株式会社 | ピラジンアミド化合物 |
MX2009013990A (es) | 2007-06-26 | 2010-03-30 | Lexicon Pharmaceuticals Inc | Metodos para tratar enfermedades y trastornos mediados por serotonina. |
CN101808518A (zh) | 2007-06-27 | 2010-08-18 | 默沙东公司 | 作为组蛋白脱乙酰酶抑制剂的吡啶基和嘧啶基衍生物 |
GB0713259D0 (en) | 2007-07-09 | 2007-08-15 | Astrazeneca Ab | Pyrazine derivatives 954 |
AR067585A1 (es) | 2007-07-19 | 2009-10-14 | Schering Corp | Compuestos heterociclicos de amidas como inhibidores de la proteincinasa |
WO2009012482A2 (en) | 2007-07-19 | 2009-01-22 | H.Lundbeck A/S | 5-membered heterocyclic amides and related compounds |
KR20100038119A (ko) | 2007-08-01 | 2010-04-12 | 화이자 인코포레이티드 | 피라졸 화합물 및 raf 억제제로서 이의 용도 |
WO2009024825A1 (en) | 2007-08-21 | 2009-02-26 | Astrazeneca Ab | 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors |
WO2009037247A1 (en) | 2007-09-17 | 2009-03-26 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
JP2011500778A (ja) | 2007-10-25 | 2011-01-06 | アストラゼネカ・アクチエボラーグ | ピリジン及びピラジン誘導体−083 |
EP2265270A1 (en) | 2008-02-04 | 2010-12-29 | OSI Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
DK2247592T3 (da) | 2008-02-25 | 2011-09-26 | Hoffmann La Roche | Pyrrolopyrazinkinaseinhibitors |
CA2716223A1 (en) | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
WO2009106444A1 (en) | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
PT2250172E (pt) | 2008-02-25 | 2011-11-30 | Hoffmann La Roche | Inibidores de pirrolpirazina-cinase |
TW200940537A (en) | 2008-02-26 | 2009-10-01 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
JP2011513332A (ja) | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | 癌の治療のためのraf阻害剤としてのn−(6−アミノピリジン−3−イル)−3−(スルホンアミド)ベンズアミド誘導体 |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
US8110576B2 (en) | 2008-06-10 | 2012-02-07 | Plexxikon Inc. | Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications |
GB0814364D0 (en) | 2008-08-05 | 2008-09-10 | Eisai London Res Lab Ltd | Diazaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase |
KR101846029B1 (ko) | 2008-08-06 | 2018-04-06 | 메디베이션 테크놀로지즈 엘엘씨 | 폴리(adp-리보오스)폴리머라아제 (parp)의 디히드로피리도프탈라지논 억제제 |
ES2378513T3 (es) | 2008-08-06 | 2012-04-13 | Pfizer Inc. | Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1 |
JP2010077286A (ja) | 2008-09-26 | 2010-04-08 | Aica Kogyo Co Ltd | シリコーン樹脂組成物および粘着フィルム |
EP2350045A1 (en) | 2008-10-21 | 2011-08-03 | Vertex Pharmaceuticals Incorporated | C-met protein kinase inhibitors |
RU2011123647A (ru) | 2008-11-10 | 2012-12-20 | Вертекс Фармасьютикалз Инкорпорейтед | Соединения, полезные в качестве ингибиторов atr киназы |
EP2379561B1 (en) | 2008-11-25 | 2015-11-04 | University Of Rochester | Mlk inhibitors and methods of use |
CA2744507A1 (en) | 2008-12-05 | 2010-06-10 | F.Hoffmann-La Roche Ag | Pyrrolopyrazinyl urea kinase inhibitors |
SG172248A1 (en) | 2008-12-19 | 2011-07-28 | Vertex Pharma | Pyrazine derivatives useful as inhibitors of atr kinase |
UY32351A (es) | 2008-12-22 | 2010-07-30 | Astrazeneca Ab | Compuestos de pirimidinil indol para uso como inhibidores de atr |
CA2748099C (en) | 2008-12-22 | 2017-02-28 | Array Biopharma Inc. | 7-phenoxychroman carboxylic acid derivatives |
MX2011006332A (es) | 2008-12-23 | 2011-06-27 | Abbott Lab | Compuestos antivirales. |
TW201036946A (en) | 2009-01-30 | 2010-10-16 | Toyama Chemical Co Ltd | N-acylanthranilic acid derivative or salt thereof |
JP5353279B2 (ja) | 2009-02-06 | 2013-11-27 | Jnc株式会社 | セレンテラミド又はその類縁体の製造方法 |
BRPI1008020A2 (pt) | 2009-02-11 | 2016-03-15 | Sunovion Pharmaceuticals Inc | antagonistas e agonistas inversos h3 da histamina e métodos de uso dos mesmos |
CN101537007A (zh) | 2009-03-18 | 2009-09-23 | 中国医学科学院血液病医院(血液学研究所) | N-(噻吩-2)吡唑并[1,5-a]嘧啶-3-甲酰胺类化合物在制备抗恶性肿瘤药物方面的应用 |
JP2012522013A (ja) | 2009-03-27 | 2012-09-20 | ザ ユーエービー リサーチ ファウンデーション | 調節ires媒介翻訳 |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
AU2010272769B2 (en) | 2009-07-13 | 2013-09-19 | T&W Engineering A/S | A hearing aid adapted for detecting brain waves and a method for adapting such a hearing aid |
EP2454262B1 (en) | 2009-07-15 | 2014-05-14 | Abbott Laboratories | Pyrrolopyrazine inhibitors of kinases |
BR112012002677A2 (pt) | 2009-08-07 | 2021-03-09 | Dow Agrosciences Llc | Moléculas de heteroaril-n-aril carbamatos, e composição pesticida |
JP2011042639A (ja) | 2009-08-24 | 2011-03-03 | Kowa Co | ビフェニルピラジン化合物及びこれを有効成分として含有するエリスロポエチン産生促進剤 |
CN101671336B (zh) | 2009-09-23 | 2013-11-13 | 辽宁利锋科技开发有限公司 | 芳杂环并嘧啶衍生物和类似物及其制备方法和用途 |
DE102009043260A1 (de) | 2009-09-28 | 2011-04-28 | Merck Patent Gmbh | Pyridinyl-imidazolonderivate |
RU2017109664A (ru) | 2009-10-06 | 2019-01-23 | Милленниум Фармасьютикалз, Инк. | Гетероциклические соединения, используемые в качестве ингибиторов pdk1 |
CA2787121C (en) | 2010-01-18 | 2018-07-17 | Mmv Medicines For Malaria Venture | Aminopyridine derivatives as anti-malarial agents |
US8518945B2 (en) | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
JP2013523805A (ja) | 2010-04-08 | 2013-06-17 | ゾエティス・エルエルシー | 殺虫剤および殺ダニ剤としての置換3,5−ジフェニル−イソオキサゾリン誘導体 |
EP2558866B1 (en) | 2010-04-15 | 2016-08-17 | Tracon Pharmaceuticals, Inc. | Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors |
EP2566858A2 (en) | 2010-05-04 | 2013-03-13 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
WO2011143419A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Pyrazines useful as inhibitors of atr kinase |
WO2011143399A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2569284B1 (en) | 2010-05-12 | 2015-07-08 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as inhibitors of atr kinase |
US9062008B2 (en) | 2010-05-12 | 2015-06-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
CA2798763A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2569287B1 (en) | 2010-05-12 | 2014-07-09 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
CN103003281A (zh) | 2010-05-20 | 2013-03-27 | 弗·哈夫曼-拉罗切有限公司 | 作为JAK和SYK抑制剂的吡咯并[2,3-b]吡嗪-7-甲酰胺衍生物和它们的用途 |
KR20130083387A (ko) | 2010-05-20 | 2013-07-22 | 에프. 호프만-라 로슈 아게 | Syk 및 jak 억제제로서 피롤로피라진 유도체 |
NZ605627A (en) | 2010-06-23 | 2015-06-26 | Vertex Pharma | Pyrrolo-pyrazine derivatives useful as inhibitors of atr kinase |
CN102311396B (zh) | 2010-07-05 | 2015-01-07 | 暨南大学 | 一种吡嗪类衍生物和其制备方法及在制药中的应用 |
EP2407478A1 (en) | 2010-07-14 | 2012-01-18 | GENETADI Biotech, S.L. | New cyclotetrapeptides with pro-angiogenic properties |
JP5782238B2 (ja) | 2010-07-30 | 2015-09-24 | ルネサスエレクトロニクス株式会社 | 電圧検出回路及びその制御方法 |
WO2012121939A2 (en) | 2011-03-04 | 2012-09-13 | Locus Pharmaceuticals, Inc. | Aminopyrazine compounds |
RU2013144579A (ru) | 2011-03-04 | 2015-04-10 | Лексикон Фармасьютикалз, Инк. | Ингибиторы киназы mst1 и способы их применения |
WO2012138938A1 (en) | 2011-04-05 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Aminopyrazine compounds useful as inhibitors of tra kinase |
EP2710006A1 (en) | 2011-05-17 | 2014-03-26 | Principia Biopharma Inc. | Azaindole derivatives as tyrosine kinase inhibitors |
EP2723747A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
WO2012178123A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US8846686B2 (en) | 2011-09-30 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
EP3878851A1 (en) | 2011-09-30 | 2021-09-15 | Vertex Pharmaceuticals Incorporated | Process for making compounds useful as inhibitors of atr kinase |
US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8765751B2 (en) | 2011-09-30 | 2014-07-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
CN103957917A (zh) | 2011-09-30 | 2014-07-30 | 沃泰克斯药物股份有限公司 | 用atr抑制剂治疗胰腺癌和非小细胞肺癌 |
EP2776419B1 (en) | 2011-11-09 | 2016-05-11 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2013071094A1 (en) * | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2776420A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
US8846917B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
PL2833973T3 (pl) | 2012-04-05 | 2018-02-28 | Vertex Pharmaceuticals Incorporated | Związki użyteczne jako inhibitory kinazy ATR i ich terapie skojarzone |
CN103373996A (zh) | 2012-04-20 | 2013-10-30 | 山东亨利医药科技有限责任公司 | 作为crth2受体拮抗剂的二并环衍生物 |
EP2904406B1 (en) | 2012-10-04 | 2018-03-21 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
WO2014062604A1 (en) | 2012-10-16 | 2014-04-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
BR112015012454B1 (pt) | 2012-12-07 | 2022-07-05 | Vertex Pharmaceuticals Incorporated | Compostos inibidores de atr quinase, seu uso e composição farmacêutica compreendendo os mesmos |
JP6096005B2 (ja) | 2013-02-26 | 2017-03-15 | リンテック株式会社 | シート剥離装置および剥離方法 |
SG11201604519PA (en) | 2013-12-06 | 2016-07-28 | Vertex Pharma | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof |
EP3152212B9 (en) | 2014-06-05 | 2020-05-27 | Vertex Pharmaceuticals Inc. | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof |
WO2015195740A1 (en) | 2014-06-17 | 2015-12-23 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of chk1 and atr inhibitors |
-
2012
- 2012-10-01 CN CN201280057951.1A patent/CN103957917A/zh active Pending
- 2012-10-01 WO PCT/US2012/058374 patent/WO2013049859A1/en active Application Filing
- 2012-10-01 ES ES20180337T patent/ES2940121T3/es active Active
- 2012-10-01 AU AU2012315384A patent/AU2012315384B2/en not_active Ceased
- 2012-10-01 IN IN2501CHN2014 patent/IN2014CN02501A/en unknown
- 2012-10-01 JP JP2014533486A patent/JP6162126B2/ja active Active
- 2012-10-01 RU RU2018108589A patent/RU2018108589A/ru unknown
- 2012-10-01 SG SG10201602515QA patent/SG10201602515QA/en unknown
- 2012-10-01 MX MX2014003785A patent/MX2014003785A/es active IP Right Grant
- 2012-10-01 EP EP20180337.6A patent/EP3733185B1/en active Active
- 2012-10-01 CA CA3089792A patent/CA3089792C/en active Active
- 2012-10-01 CA CA2850491A patent/CA2850491C/en active Active
- 2012-10-01 ES ES12772860T patent/ES2899880T3/es active Active
- 2012-10-01 US US13/633,114 patent/US20130089626A1/en not_active Abandoned
- 2012-10-01 CN CN201810375517.7A patent/CN108464983A/zh active Pending
- 2012-10-01 EP EP12772860.8A patent/EP2750679B1/en active Active
- 2012-10-01 RU RU2014117666A patent/RU2648507C2/ru active
- 2012-10-01 BR BR112014007690-1A patent/BR112014007690B1/pt active IP Right Grant
- 2012-10-01 CN CN201810375541.0A patent/CN108685922A/zh active Pending
- 2012-10-01 SG SG11201401095YA patent/SG11201401095YA/en unknown
- 2012-10-01 KR KR1020147011670A patent/KR102056586B1/ko active IP Right Grant
-
2014
- 2014-02-28 US US14/193,845 patent/US10813929B2/en active Active
- 2014-03-28 MX MX2019006684A patent/MX2019006684A/es unknown
- 2014-03-30 IL IL231813A patent/IL231813B/en active IP Right Grant
- 2014-04-10 ZA ZA2014/02627A patent/ZA201402627B/en unknown
-
2017
- 2017-04-07 JP JP2017076560A patent/JP2017119724A/ja not_active Withdrawn
- 2017-07-20 AU AU2017206224A patent/AU2017206224A1/en not_active Abandoned
-
2018
- 2018-05-11 JP JP2018092027A patent/JP2018119014A/ja active Pending
-
2019
- 2019-05-09 AU AU2019203240A patent/AU2019203240B2/en not_active Ceased
- 2019-12-19 JP JP2019229321A patent/JP7162585B2/ja active Active
-
2020
- 2020-08-26 US US17/003,554 patent/US20200390761A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014528423A5 (ja) | ||
King et al. | Use of amifostine for cytoprotection during radiation therapy: a review | |
RU2014117666A (ru) | Лечение рака поджелудочной железы и немелкоклеточного рака легкого ингибиторами атr | |
Lawrence et al. | The mechanism of action of radiosensitization of conventional chemotherapeutic agents | |
PH12017501500A1 (en) | Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy | |
CY1118216T1 (el) | Μεθοδοι αγωγης καρκινου | |
TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
MX2017016492A (es) | Metodos para tratar tumores solidos usando terapia de combinacion de nanoparticula del inhibidor del objetivo mamifero de la rapamicina (mtor). | |
BR112014016163A8 (pt) | piridoftalazinonas tetra ou penta-cíclicas fundidas como inibidores de parp | |
MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
NZ729643A (en) | Combination therapy for treating cancer | |
NZ708506A (en) | Methods of treating bladder cancer | |
WO2009008992A3 (en) | Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2 | |
WO2012159085A3 (en) | Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells | |
WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
JP2012523435A5 (ja) | ||
JP2017519006A5 (ja) | ||
JP2014530181A5 (ja) | ||
JP2016522826A5 (ja) | ||
JP2011500650A5 (ja) | ||
BR112015005392A2 (pt) | formulação de comprimido de um inibidor de fosfatidilinositol 3-cinase | |
Guo et al. | Synergistic antitumor interactions between gemcitabine and clofarabine in human pancreatic cancer cell lines | |
Shengye et al. | Effect of amifostine on locally advanced non-small cell lung cancer patients treated with radiotherapy: a meta-analysis of randomized controlled trials | |
Ragulin et al. | COMPARATIVE EVALUATION OF NON-CONVENTIONAL RADIATION AND CHEMORADIATION IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER | |
Han ChunYan et al. | Capecitabine combined with late course accelerated hyperfractionated radiotherapy for esophageal cancer. |